Crispr Therapeutics Selling General Administrative Over Time
| CRSP Stock | USD 51.24 3.91 7.09% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Crispr Therapeutics Performance and Crispr Therapeutics Correlation. Crispr |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Crispr Therapeutics. If investors know Crispr will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Crispr Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.79) | Revenue Per Share 2.446 | Quarterly Revenue Growth (0.99) | Return On Assets (0.1) | Return On Equity (0.13) |
The market value of Crispr Therapeutics is measured differently than its book value, which is the value of Crispr that is recorded on the company's balance sheet. Investors also form their own opinion of Crispr Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Crispr Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Crispr Therapeutics' market value can be influenced by many factors that don't directly affect Crispr Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Crispr Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Crispr Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Crispr Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Selling General Administrative Analysis
Compare Crispr Therapeutics and related stocks such as Beam Therapeutics, Editas Medicine, and Caribou Biosciences Selling General Administrative Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BEAM | 2 M | 2 M | 2 M | 2 M | 2 M | 2 M | 2 M | 2 M | 11.9 M | 20.6 M | 29.6 M | 57.2 M | 87.8 M | 116.8 M | 122.7 M |
| EDIT | 7.7 M | 7.7 M | 7.7 M | 7.7 M | 7.7 M | 18.1 M | 46.3 M | 50.5 M | 55 M | 64.6 M | 67.6 M | 76.2 M | 70.7 M | 69.7 M | 57.9 M |
| CRBU | 16.5 M | 16.5 M | 16.5 M | 16.5 M | 16.5 M | 16.5 M | 16.5 M | 16.5 M | 16.5 M | 16.5 M | 14.1 M | 24.3 M | 38 M | 38.5 M | 28.9 M |
| VERV | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 5.3 M | 18.9 M | 37.5 M | 49.9 M | 25.1 M |
| NTLA | 3.6 M | 3.6 M | 3.6 M | 3.6 M | 3.6 M | 8.3 M | 16.8 M | 28 M | 32.2 M | 41.1 M | 44.2 M | 71.1 M | 90.3 M | 116.5 M | 122.3 M |
| FATE | 4.6 M | 4.6 M | 4.2 M | 6.6 M | 8.5 M | 10.4 M | 9.9 M | 11.9 M | 15.8 M | 23.6 M | 33.9 M | 57.3 M | 84.2 M | 81.4 M | 85.5 M |
| REGN | 5.8 M | 117.3 M | 210.8 M | 329.4 M | 504.8 M | 838.5 M | 1.2 B | 1.3 B | 1.6 B | 1.8 B | 1.3 B | 1.8 B | 2.1 B | 2.6 B | 2.7 B |
| NVO | 1.2 B | 3.2 B | 3.3 B | 3.5 B | 3.5 B | 3.9 B | 4 B | 3.8 B | 3.9 B | 4 B | 4 B | 4 B | 4.5 B | 4.9 B | 6.5 B |
| SRPT | 600 K | 16.1 M | 14.6 M | 31.6 M | 49.3 M | 75 M | 81.2 M | 119.8 M | 210 M | 284.8 M | 317.9 M | 282.7 M | 451.4 M | 453.3 M | 475.9 M |
| HEPA | 106.4 K | 106.4 K | 106.4 K | 1.4 M | 1.4 M | 5.6 M | 5.8 M | 7.4 M | 7 M | 4.6 M | 8.1 M | 10 M | 10.3 M | 9.6 M | 6.5 M |
| KRYS | 402 K | 402 K | 402 K | 402 K | 402 K | 402 K | 402 K | 1.6 M | 4.2 M | 6.5 M | 15.1 M | 40.4 M | 77.7 M | 98.4 M | 103.3 M |
Crispr Therapeutics and related stocks such as Beam Therapeutics, Editas Medicine, and Caribou Biosciences Selling General Administrative description
My Equities
My Current Equities and Potential Positions
| Crispr Therapeutics AG | CRSP |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Switzerland |
| Exchange | NASDAQ Exchange |
USD 51.24
Additional Tools for Crispr Stock Analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.